{
    "clinical_study": {
        "@rank": "3310", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods"
            }, 
            {
                "arm_group_label": "Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods"
            }, 
            {
                "arm_group_label": "Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods"
            }, 
            {
                "arm_group_label": "Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods"
            }, 
            {
                "arm_group_label": "Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods"
            }, 
            {
                "arm_group_label": "Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed", 
                "arm_group_type": "Other", 
                "description": "Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and\n      Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral\n      administration relative to 2.5-mg Saxagliptin and 5-mg Dapagliflozin tablets administered\n      orally together in the fasted state and to demonstrate the BE of Saxagliptin and\n      Dapagliflozin from a 5-mg Saxagliptin/10-mg Dapagliflozin FDC tablet after oral\n      administration relative to 5-mg Saxagliptin and 10-mg Dapagliflozin tablets administered\n      orally together in the fasted state.  Demonstrating bioequivalence refers to showing that\n      the FDC tablet and co-administration of the individual components yield similar blood\n      levels/concentrations of the drug and are handled by the body similarly."
        }, 
        "brief_title": "Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose: This study is designed to demonstrate the bioequivalence of Saxagliptin and\n      Dapagliflozin from a FDC tablet after oral administration relative to Saxagliptin and\n      Dapagliflozin tablets administered orally together in the fasted and fed state"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, physical examination (PE), vital signs, 12-lead ECG, and clinical\n             laboratory determinations\n\n          -  Body mass index (BMI) of 18.5 to 30 kg/m(2)\n\n          -  Men and women, ages 18 to 50 years\n\n          -  Women of childbearing potential must use acceptable methods of highly effective birth\n             control\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Current or recent gastrointestinal disease\n\n          -  Any major surgery within 4 weeks of study drug administration\n\n          -  History of chronic or recurrent urinary tract infection for females\n\n          -  History of glucose intolerance or diabetes mellitus\n\n          -  History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or\n             Sodium-glucose cotransporter (SGLT) inhibitors\n\n          -  Prior exposure to Saxagliptin or Dapagliflozin or related drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060201", 
            "org_study_id": "CV181-341"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting", 
                    "Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting"
                ], 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Onglyza\u00ae", 
                    "BMS-477118"
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting", 
                    "Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting"
                ], 
                "intervention_name": "Dapagliflozin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Farxiga\u00ae", 
                    "Forxiga\u00ae", 
                    "BMS-512148"
                ]
            }, 
            {
                "arm_group_label": [
                    "Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting", 
                    "Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed", 
                    "Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting", 
                    "Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed"
                ], 
                "intervention_name": "Saxagliptin/Dapagliflozin FDC", 
                "intervention_type": "Drug", 
                "other_name": "BMS-986098"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Saxagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 10, 2014", 
        "number_of_arms": "6", 
        "official_title": "A Bioequivalence Study of 2.5-mg Saxagliptin/5-mg Dapagliflozin and 5-mg Saxagliptin/10-mg Dapagliflozin Fixed Dose Combination Tablets Relative to Coadministration of Their Respective Individual Components in Healthy Subjects and a Characterization of the Effect of Food on the Fixed Dose Combination Tablets", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) for Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [(AUC(0-T)] for Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero extrapolated to infinite time [(AUC(INF)] for Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060201"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax for 5-hydroxy (OH) Saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "54 time points up to 15 days"
            }, 
            {
                "measure": "AUC(0-T) for 5-hydroxy (OH) Saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "54 time points up to 15 days"
            }, 
            {
                "measure": "AUC(INF) for 5-hydroxy (OH) Saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "54 time points up to 15 days"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Percent of AUC extrapolated from last quantifiable concentration to infinity (pAUCe) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Half life (T HALF) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Terminal disposition rate constant (Lambda) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Time point where log-linear elimination begins (TLIN) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Time at which the last concentration occurred that is above the lower limit of quantitation (LQCT) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin", 
                "safety_issue": "No", 
                "time_frame": "54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days"
            }, 
            {
                "measure": "Safety measured by the occurrence of deaths, adverse events (AEs), serious adverse events (SAEs), results of clinical laboratory tests, vital sign measurements, physical examination findings, and 12-lead electrocardiogram (ECG) results", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 16 days"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}